Involved-node radiotherapy in early-stage Hodgkin's lymphoma
HT Eich, RP Müller… - Strahlentherapie …, 2008 - search.proquest.com
HT Eich, RP Müller, R Engenhart-Cabillic, P Lukas, H Schmidberger, S Staar, N Willich
Strahlentherapie und Onkologie, 2008•search.proquest.comRadiotherapy of Hodgkin's lymphoma has evolved from extended-field to involved-field (IF)
radiotherapy reducing toxicity whilst maintaining high cure rates. Recent publications
recommend further reduction in the radiation field to involved-node (IN) radiotherapy;
however, this concept has never been tested in a randomized trial. The German Hodgkin
Study Group aims to compare it with standard IF radiotherapy in their future HD17 trial.
radiotherapy reducing toxicity whilst maintaining high cure rates. Recent publications
recommend further reduction in the radiation field to involved-node (IN) radiotherapy;
however, this concept has never been tested in a randomized trial. The German Hodgkin
Study Group aims to compare it with standard IF radiotherapy in their future HD17 trial.
Abstract
Radiotherapy of Hodgkin's lymphoma has evolved from extended-field to involved-field (IF) radiotherapy reducing toxicity whilst maintaining high cure rates. Recent publications recommend further reduction in the radiation field to involved-node (IN) radiotherapy; however, this concept has never been tested in a randomized trial. The German Hodgkin Study Group aims to compare it with standard IF radiotherapy in their future HD17 trial.
ProQuest